## Programme

### Wednesday 14 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2: Symposium on Novel Coronaviruses</th>
<th>Session 3: Oral Abstract Session 1- Emerging threats</th>
</tr>
</thead>
</table>
| 08:00-08:20 | Opening & Welcome  
HongZhou Lu, Fudan University & SPHCC, Shanghai, China (Chair Organising Committee) and Alan Hay, Francis Crick Institute, London, UK (Chair isirv-AVG) |  |
| 08:20-09:00 | Session 1  
Chairs: HongZhou Lu, Fudan University & SPHCC, Shanghai, China (Chair Organising Committee) and Alan Hay, Francis Crick Institute, London, UK (Chair isirv-AVG)  
Keynote Lecture  
Zoonotic Respiratory Viral Threats at the Animal-Human Interface  
Malik Peiris, University of Hong Kong, Hong Kong SAR, China | Session 2: Symposium on Novel Coronaviruses  
Chairs: Malik Peiris, University of Hong Kong, Hong Kong SAR, China and Chen Wang, China-Japan Friendship Hospital, Beijing, China (TBC)  
Insights from Pre-clinical Models of MERS and SARS  
Ralph Baric, University of North Carolina, Chapel Hill, North Carolina, USA  
Clinical Features and the Virologic Course of MERS  
Myoung-don Oh, Seoul National University, Seoul, Korea  
Recovery from Middle East Respiratory Syndrome is associated with both Antibody and T cell responses  
Jincun Zhao, State Key Lab of Respiratory Disease, Guangzhou, China  
Advances in Developing Vaccines and Therapeutics against MERS-CoV  
Shibo Jiang, Fudan University, Shanghai, China |  |
| 10:40 -10:55 | Celebration of Designation of the SPHCC as a WHO Collaborating Centre |  |
| 10:55 -11:25 | Refreshments |  |
| 11:25 -13:00 | Session 3: Oral Abstract Session 1- Emerging threats  
Chairs: HongZhou Lu, Fudan University & SPHCC, Shanghai, China and Menno de Jong, University of Amsterdam, Amsterdam, Holland  
Introductory talk- Lessons from Nosocomial Outbreaks of MERS  
Sang Won Park, Seoul National University College of Medicine, Seoul, Korea  
Human Adenovirus Type 80: A Novel Adenovirus Causing ARDS and Disseminated Infection with Fatal Outcome  
Barbara Rath, Vienna Vaccine Safety Initiative, Berlin, Germany |  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:00 -14:00 | **Lunchtime Seminar: An Introduction to Influenza Treatment with Traditional Chinese Medicine**  
**Sponsored by Anhui Jiren Pharmaceutical Co., LTD**  
**Chair:** HongZhou Lu, Fudan University & SPHCC, Shanghai, China |
|            | Basic Research Status of Prevention and Treatment of Virus Infectious Diseases by Traditional Chinese Medicine (TCM)  
Cui Xiao-lan, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China |
|            | Study on the Effective Substance, Mechanism, Compatibility and Rationale of Shufeng Jiedu Capsule (SJC)  
Zhang Tiejun, Tianjin Institute of Pharmaceutical Research, State Key Laboratory of Drug Delivery Technology and Pharmacokinetics & Tianjin Engineering Laboratory of Quality Control Technology of Traditional Chinese Medicine, Tianjin, China |
|            | Therapeutic Mechanism Studies of SFJDC in Acute Lung Injury Using Quantitative Proteomics Technology  
Catherine CL Wong, National Center for Protein Science, Shanghai, China |
| 14:00 -15:35 | **Session 4: Avian A(H7N9) Influenza**  
**Chairs:** Yuelong Shu, China CDC, Beijing, China and David Hui, Chinese University of Hong Kong, Hong Kong SAR, China |
|            | Infection Prevention and Control for Patients with Avian Influenza A (H7N9) Virus Infection  
Yinzhong Shen, Shanghai Fudan University, China |
|            | Epidemiology of Human Infections with A(H7N9) Virus and Control Measures in mainland China  
Lei Zhou, China CDC, Beijing, China |
|            | Virological Update  
Yuelong Shu, China CDC, Beijing, China |
|            | Antiviral Treatment and Resistance  
Junwen Hu, Shanghai Fudan University, China |
| 15:35-16:00 | **Refreshments**                                                                               |
| 16:00-18:05 | **Session 5: Oral Abstract Session 2- RVI Diagnosis and Treatment**  
**Chairs:** Yi-Wei Tang, Memorial Sloan Kettering, New York, USA and Karoline Bragstad, NIC, Oslo, Norway |
|            | **Introductory Talk**- Advances in RVI Molecular Diagnostics  
Yi-Wei Tang, Memorial Sloan Kettering, New York, USA |
|            | Routine Molecular Point-of-Care Testing for Respiratory Viruses in Adults  
Presenting to Hospital with Acute Respiratory Illness: Results of a Large, Pragmatic, Randomised Controlled Trial  
Tristan Clark, University of Southampton, Southampton, UK |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30-21:00</td>
<td>Conference Networking Dinner</td>
</tr>
</tbody>
</table>

**Thursday 15 June**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:40</td>
<td><strong>Session 6:</strong>&lt;br&gt;Chairs: Bin Cao, China-Japan Friendship Hospital, Beijing, China and Yinzong Shen Shanghai Fudan University, China&lt;br&gt; <strong>Keynote Lecture</strong>&lt;br&gt; Burden of Influenza and Other Respiratory Viruses in China&lt;br&gt; Hongjie Yu, Chinese Centre for Disease Control, Beijing, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40-10:00</td>
<td><strong>Session 7: Oral Abstract Session 3 - RVI Impact and CAP</strong>&lt;br&gt;Chairs: Professor Nan-Shan Zhong, Guangzhou Medical University, Guangzhou, China and Myoung-don Oh, Seoul National University, Seoul, Korea&lt;br&gt; <strong>Introductory Talk:</strong> Chinese guidelines for CAP 2016&lt;br&gt; Jieming Qu, Shanghai Ruijin Hospital, Shanghai, China&lt;br&gt; Comparison of Self-Reported Contact Patterns Between Hospital-Based Healthcare Workers and Working Adults From the General Population and Its Implications for Infectious Disease Transmission&lt;br&gt; Lili Jiang, National University of Singapore, Singapore&lt;br&gt; Difference in Clinical Presentation of Human Metapneumovirus Group-A Lineages Associated with Paediatric ARI Hospitalizations in Central Vietnam during 2007-2015&lt;br&gt; Keisuke Yoshihara, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan&lt;br&gt; The Genomic and Epidemiological Dynamics of Respiratory Syncytial Virus in New South Wales, Australia Between 2010-2016&lt;br&gt; John-Sebastian Eden, The University of Sydney, Sydney, NSW, Australia&lt;br&gt; Etiology and Incidence of Severe Acute Respiratory Infection Among Hospitalized Patients in Antananarivo, Madagascar, 2014-2016&lt;br&gt; Norosoa Razanajatovo, Institut Pasteur de Madagascar, Antananarivo, Madagascar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 -10:30</td>
<td>Refreshments</td>
</tr>
</tbody>
</table>
10:30-12:00  Session 8: Oral Abstract Session 4- Pathogenesis of SARI
Chairs: Ralph Baric, University of North Carolina, Chapel Hill, NC, USA
        and Peter Openshaw Imperial College, London, United Kingdom

Introductory Talk- What Part do Bacteria Play in Severe Influenza?
Peter Openshaw, Imperial College, London, United Kingdom

Severity and Phase Linked Virus Specific CD4 and CD8 T Cell Responses in Human pH1N1 Infection
Hui Li, Capital Medical University, Beijing, China

AIM2 Inflammasome is Critical for Influenza Induced Lung Injury and Mortality
Jieru Wang, University of Pittsburgh, Pittsburgh, USA

Identification of DDX19B as an Essential Host Factor for Uncoating Step During Influenza Virus Entry
Jihye Lee, Institut Pastuer Korea, Republic of Korea

Studies to Gain Insights into Drug Resistance of Influenza A(H7N9) Viruses
Larisa Gubareva, Centers for Disease Control and Prevention, Atlanta, GA, USA

12:00 – 13:00  Lunchtime Seminar: The GISAID Initiative
Chair: George Gao, Chinese Academy of Sciences, Beijing, China

The Importance and Contribution of GISAID
George Gao, Chinese Academy of Sciences, Beijing, China

GISAID in Surveillance and Pandemic Preparedness
Yang Lei, China CDC, Beijing, China

The EpiFlu Database
Naomi Komadina, WHO Influenza Collaborating Centre, Melbourne, Australia

Analysis and Interpretation of Influenza Genetic Data
Raphael Tze-Cheun Lee, Bioinformatics Institute, A*STAR, Singapore

13:00 -15:00  Session 9: Symposium on RVI Therapeutics
Chairs: George Gao, Chinese Academy of Sciences, Beijing, China and Amy Krafft, NIAID, Bethesda, Maryland, USA,

Understanding Antiviral Targets
Yoshi Kawaoka, University of Wisconsin, Madison Wisconsin USA and University of Tokyo, Tokyo, Japan

Prospects for Antivirals for RSV Disease
Peter Openshaw, Imperial College, London, United Kingdom

Novel RSV Inhibitor AK0529: Update on Clinical Development
Stephen Toovey, Chief Medical Officer, Ark Biosciences

Usefulness of Probiotics for RVI Mitigation
Lisa Lehtoranta, DuPont Nutrition & Health, Kantvik, Finland

Which Traditional Chinese Medicines are Most Beneficial?
Bin Cao, China-Japan Friendship Hospital, Beijing, China

15:00 – 15:30  Refreshments

15:30 – 17:45  Session 10: Oral Abstract Session 5 - Short Presentations on Developments of Influenza Antivirals
Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, USA and Aeron Hurt, WHO Influenza Collaborating Centre, Melbourne, Australia

Introductory Talk: Building The Pre-Clinical Pipeline for Influenza Therapeutics
Amy Krafft, NIAID, Bethesda, Maryland, USA
### Invited Topics:

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pimodivir (JNJ-63623872): a brief overview</td>
<td>Lorant Leopold, Janssen, Titusville, New Jersey, USA</td>
</tr>
<tr>
<td>Cap-dependent Endonuclease Inhibitor S-033188</td>
<td>Takeki Uehara, Shionogi, Osaka, Japan</td>
</tr>
<tr>
<td>MHAA4549A Monoclonal</td>
<td>Man Wah Tan, Genentech, South San Francisco, California, USA</td>
</tr>
<tr>
<td>VIS410 Monoclonal</td>
<td>Jose Trevejo, Visterra, Cambridge, Massachusetts, USA</td>
</tr>
<tr>
<td>Experience with Favipiravir in Phase 3 and Implications for Future Studies</td>
<td>Carol Epstein, Fujifilm Pharmaceuticals USA, Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>Nitazoxanide: A First-in-Class Indirect-Acting Antiviral for Treatment of Respiratory Virus Infections</td>
<td>Jean-Francois Rossignol, Romark, Morristown, New Jersey, USA</td>
</tr>
<tr>
<td>IV Zanamivir</td>
<td>Sumita Roy-Ghanta, GSK, Philadelphia, Pennsylvania, USA</td>
</tr>
<tr>
<td>Umifenovir (Arbidol) – Antiviral Drug Against Influenza Viruses</td>
<td>Irina Leneva, Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia</td>
</tr>
<tr>
<td>Oral Danirixin (GSK1325756)</td>
<td>Sumita Roy-Ghanta, GSK, Philadelphia, Pennsylvania, USA</td>
</tr>
<tr>
<td>Developing Therapeutic Human Antibodies from Transchromosomal (Tc) Bovine to Treating Influenza Infection</td>
<td>Hua Wu, SAb Biotherapeutics, Sioux Falls, SD, USA</td>
</tr>
</tbody>
</table>

### 17:45 – 19:30

**Poster Session Reception** – Sponsored by Gilead Sciences, Inc

### Friday 16 June

#### 08:00 – 08:45

**Session 11:**

**Chairs:** Arnold Monto, University of Michigan School of Public Health, Ann Arbor, USA and Yinzhong Shen, Fudan University and SPHCC, Shanghai, China

**Keynote Lecture**

**Advances in Vaccines for Respiratory Viral Infections**

*Barney Graham, Vaccine Research Center, NIAID, Bethesda, Maryland, USA*

#### 08:45 – 10:30

**Session 12: Oral Abstract Session 6- Vaccines and Preventive Strategies**

**Chairs:** Barney Graham, Vaccine Research Center, NIAID, Bethesda, Maryland, USA and Arnold Monto, University of Michigan School of Public Health, Ann Arbor, USA

**Introductory Talk- Protective Immunity During Natural H7N9 Infection in Humans**

*Jianqing Xu, Shanghai Public Health Clinical Center, Shanghai, China*

**Natural H7N9 Infection in Humans Boosts Cross-Group Stalk-Specific Antibody Responses**

*Lu Liu, Shanghai Public Health Clinical Center, Shanghai, China*

**A Single IM Dose of a Plant-Made VLP Vaccine Bearing the H1 Hemagglutinin Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Challenge**

*Breanna Hodgins, McGill University, Montreal, Quebec, Canada*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
<td>Refreshments</td>
</tr>
<tr>
<td>11:00-13:00</td>
<td><strong>Session 13: Discussion on Clinical Research Issues</strong>&lt;br&gt;<strong>Chairs:</strong> Kimberly Armstrong, BARDA, Washington, USA and Michael Ison, Northwestern University, Chicago, Illinois, USA&lt;br&gt;Updating the WHO Influenza Research Agenda&lt;br&gt;Jacky Chan, WHO, Geneva, Switzerland&lt;br&gt;What Endpoints Make Sense in Clinical Trials of Severe Influenza and Related Illnesses?&lt;br&gt;Menno de Jong, University of Amsterdam, Amsterdam, Holland&lt;br&gt;Developing Influenza Therapeutics - A European Regulator's Perspective&lt;br&gt;Regine Lehnert, BfArM, Germany&lt;br&gt;Feasible or Infeasible? Investigational Drug Monotherapy for Patients Hospitalised with Laboratory-Confirmed Influenza&lt;br&gt;Kimberley Armstrong, BARDA, Washington, DC, USA&lt;br&gt;Roundtable Discussion</td>
</tr>
<tr>
<td>13:00 -14:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00 -16:00</td>
<td><strong>Session 14: Symposium on Issues in Clinical Management</strong>&lt;br&gt;<strong>Chairs:</strong> Guanghe Fei, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China and Norio Sugaya, Keiyu Hospital, Yokahama, Japan&lt;br&gt;Under-Recognized and Unusual Presentations of Influenza&lt;br&gt;William Fischer, University of North Carolina, Chapel Hill, North Carolina, USA&lt;br&gt;Managing RVIs in Transplant Recipients&lt;br&gt;Michael Ison, Northwestern University, Chicago, Illinois, USA&lt;br&gt;Corticosteroids, Statins, and Other Adjunctive Therapies in SARI&lt;br&gt;David Hui, Chinese University of Hong Kong, Hong Kong SAR, China&lt;br&gt;Mutagenesis analysis to identify determinants for neuraminidase inhibitor resistance in influenza viruses of N8 and N9 subtypes&lt;br&gt;Hui-Ling Yen, University of Hong Kong, Hong Kong SAR, China&lt;br&gt;Q &amp; A Panel</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>